Abstract
This is an update to the EtR framework for the following policy question:
Should individuals ages 5–11 years receive a Pfizer-BioNTech COVID-19 vaccine booster dose at least 5 months after completion of the primary series, based on the balance of benefits and risks?
Presented during the meeting of May 19th 2022.
Background paper
Americas
United States of America
children
COVID-19
